Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Generation Bio Co.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 NEW DATA CONFIRM HIGHLY SELECTIVE PROFILE OF CELL-TARGETED LIPID NANOPARTICLE (CTLNP) AND FIRST-EVER SIRNA DELIVERY TO T CELLS IN NON-HUMAN PRIMATES LEAD SIRNA CANDIDATES SHOW POTENT KNOCKDOWN OF LAT1 AND VAV1, TARGETS POTENTIALLY RELEVANT TO T CELL-DRIVEN AUTOIMMUNE DISEASES COMPANY IS EVALUATING STRATEGIC ALTERNATIVES TO MAXIMIZE VALUE OF ITS DELIVERY SYSTEM AND POTENTIAL THERAPEUTICS FOR T CELL-DRIVEN AUTOIMMUNE DISEASES FOR SHAREHOLDERS CASH BALANCE OF $141.4M AS OF JUNE 30, 2025 RECENT LITIGATION SETTLEMENT EXTINGUISHES LEASE LIABILITY CAMBRIDGE, MASS., AUG. 12, 2025 (GLOBE NEWSWIRE) -- GENERATION BIO CO. (NASDAQ: GBIO), A BIOTECHNOLOGY COMPANY WORKING TO CHANGE WHAT'S POSSIBLE FOR PEOPLE LIVING WITH T CELL-DRIVEN AUTOIMMUNE DISEASES, TODAY ANNOUNCED NEW DATA DEMONSTRATING THAT ITS CELL-TARGETED LIPID NANOPARTICLE (CTLNP) SYSTEM SELECTIVELY DELIVERED SIRNA TO T CELLS IN NON-HUMAN PRIMATES, REINFORCING THE COMPANY'S BELIEF THAT ITS CTLNP HAS THE ABILITY TO DELIVER DIVERSE GENETIC MEDICINE PAYLOADS TO MULTIPLE NEW CELL TYPES.

GENERATION BIO ANNOUNCES NEW DATA FOR ITS NOVEL CTLNP DELIVERY SYSTEM AND EARLY T CELL PROGRAMS AND REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

CAMBRIDGE, MASS., JULY 18, 2025 (GLOBE NEWSWIRE) -- GENERATION BIO CO. (NASDAQ: GBIO), A BIOTECHNOLOGY COMPANY WORKING TO CHANGE WHAT'S POSSIBLE FOR PEOPLE LIVING WITH T CELL-DRIVEN AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT IT WILL IMPLEMENT A 1-FOR-10 REVERSE STOCK SPLIT OF THE ISSUED SHARES OF THE COMPANY'S COMMON STOCK (REVERSE STOCK SPLIT), EFFECTIVE AT 5:00 PM EASTERN TIME ON JULY 21, 2025. THE REVERSE STOCK SPLIT WAS APPROVED BY THE COMPANY'S STOCKHOLDERS AT THE COMPANY'S ANNUAL MEETING OF STOCKHOLDERS HELD ON JUNE 4, 2025, WITH THE FINAL RATIO SUBSEQUENTLY DETERMINED BY THE COMPANY'S BOARD OF DIRECTORS. ONE OF THE PRIMARY GOALS OF THE REVERSE STOCK SPLIT IS TO INCREASE THE PER-SHARE MARKET PRICE OF THE COMPANY'S COMMON STOCK TO ENABLE THE COMPANY TO REGAIN COMPLIANCE WITH THE MINIMUM BID PRICE REQUIREMENT FOR CONTINUED LISTING ON THE NASDAQ GLOBAL SELECT MARKET.

GENERATION BIO ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT

CAMBRIDGE, MASS., JULY 07, 2025 (GLOBE NEWSWIRE) -- GENERATION BIO CO. (NASDAQ:GBIO), A BIOTECHNOLOGY COMPANY WORKING TO CHANGE WHAT'S POSSIBLE FOR PEOPLE LIVING WITH T CELL-DRIVEN AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT, ON JULY 1, 2025, THE COMPANY GRANTED EQUITY AWARDS TO ONE NEW EMPLOYEE, PURSUANT TO THE COMPANY'S 2025 INDUCEMENT STOCK INCENTIVE PLAN, AS AN INDUCEMENT MATERIAL TO SUCH NEW EMPLOYEE'S ENTERING INTO EMPLOYMENT WITH THE COMPANY IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

GENERATION BIO ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

CAMBRIDGE, MASS., MAY 28, 2025 (GLOBE NEWSWIRE) -- GENERATION BIO CO. (NASDAQ:GBIO), A BIOTECHNOLOGY COMPANY WORKING TO CHANGE WHAT'S POSSIBLE FOR PEOPLE LIVING WITH T CELL-DRIVEN AUTOIMMUNE DISEASES, ANNOUNCED THAT GEOFF MCDONOUGH, M.D.

GENERATION BIO TO PRESENT AT THE 2025 JEFFERIES GLOBAL HEALTHCARE CONFERENCE

- COMPANY CONTINUES TO ADVANCE ITS STRATEGY TO DEVELOP FIRST-IN-CLASS TREATMENTS FOR T CELL-DRIVEN AUTOIMMUNE DISEASES USING ITS CELL-TARGETED LIPID NANOPARTICLE (CTLNP) TECHNOLOGY TO DELIVER SIRNA - LEAD TARGET AND PORTFOLIO STRATEGY TO BE ANNOUNCED MID-2025 - CASH BALANCE OF $157.6 MILLION EXPECTED TO FUND OPERATIONS INTO 2H 2027 CAMBRIDGE, MASS., MAY 07, 2025 (GLOBE NEWSWIRE) -- GENERATION BIO CO. (NASDAQ: GBIO), A BIOTECHNOLOGY COMPANY WORKING TO CHANGE WHAT'S POSSIBLE FOR PEOPLE LIVING WITH T CELL-DRIVEN AUTOIMMUNE DISEASES, REPORTED BUSINESS HIGHLIGHTS AND FIRST QUARTER 2025 FINANCIAL RESULTS.

GENERATION BIO REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2025 FINANCIAL RESULTS

CAMBRIDGE, MASS., APRIL 02, 2025 (GLOBE NEWSWIRE) -- GENERATION BIO CO. (NASDAQ:GBIO), A BIOTECHNOLOGY COMPANY WORKING TO CHANGE WHAT'S POSSIBLE FOR PEOPLE LIVING WITH T CELL-DRIVEN AUTOIMMUNE DISEASES, ANNOUNCED THAT GEOFF MCDONOUGH, M.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 24TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE ON WEDNESDAY, APRIL 9TH AT 12:45 P.M. ET.

GENERATION BIO TO PRESENT AT THE NEEDHAM 24TH ANNUAL VIRTUAL HEALTHCARE CONFERENCE

- COMPANY IS APPLYING ITS T CELL-SELECTIVE LIPID NANOPARTICLE TO DEVELOP SIRNA THERAPEUTICS FOR T CELL-DRIVEN AUTOIMMUNE DISEASES

GENERATION BIO REPORTS BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

CAMBRIDGE, MASS., FEB. 24, 2025 (GLOBE NEWSWIRE) -- GENERATION BIO CO. (NASDAQ:GBIO), A BIOTECHNOLOGY COMPANY WORKING TO CHANGE WHAT'S POSSIBLE FOR PEOPLE LIVING WITH T CELL-DRIVEN AUTOIMMUNE DISEASES, ANNOUNCED THAT GEOFF MCDONOUGH, M.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PRESENT AT THE TD COWEN 45TH ANNUAL HEALTH CARE CONFERENCE ON MONDAY, MARCH 3, 2025 AT 9:10 A.M. ET IN BOSTON.

GENERATION BIO TO PRESENT AT THE TD COWEN 45TH ANNUAL HEALTH CARE CONFERENCE

MUNICH, GERMANY--(BUSINESS WIRE)--TUBULIS TODAY ANNOUNCED THE APPOINTMENT OF MATTHEW NORKUNAS, MD, MBA, AS CHIEF FINANCIAL OFFICER (CFO) AND PRESIDENT OF TUBULIS INC., FURTHER STRENGTHENING ITS MANAGEMENT TEAM AT A PIVOTAL STAGE OF GROWTH. DR. NORKUNAS' PROVEN TRACK RECORD OF ACHIEVING FINANCIAL AND CORPORATE GOALS FOR RAPIDLY EVOLVING BIOTECHS WILL BE INSTRUMENTAL IN ADVANCING TUBULIS' STRATEGIC OBJECTIVES. HIS UNIQUE BACKGROUND AS A PHYSICIAN-TURNED-BUSINESS EXECUTIVE WILL SUPPORT THE COMPANY.

TUBULIS STRENGTHENS EXECUTIVE LEADERSHIP WITH APPOINTMENT OF MATTHEW NORKUNAS AS CHIEF FINANCIAL OFFICER AND PRESIDENT OF TUBULIS INC.

CAMBRIDGE, MASS., JAN. 06, 2025 (GLOBE NEWSWIRE) -- GENERATION BIO CO. (NASDAQ:GBIO) A BIOTECHNOLOGY COMPANY WORKING TO CHANGE WHAT IS POSSIBLE FOR PEOPLE LIVING WITH T CELL-DRIVEN AUTOIMMUNE DISEASES, ANNOUNCED IT IS LEVERAGING ITS VALIDATED T CELL-DIRECTED LIPID NANOPARTICLE (CTLNP) TO DEVELOP SIRNA THERAPEUTICS TO SILENCE DISEASE-DRIVING TARGETS IN T CELLS. WE ARE EXCITED TO MOVE GENERATION BIO TOWARD THE CLINIC BY DEPLOYING OUR CTLNP TO DELIVER SIRNA TO T CELLS. BY PRECISELY MODULATING T CELL ACTIVITY IN VIVO WE BELIEVE WE CAN ADDRESS HIGH-VALUE, CURRENTLY UNDRUGGABLE TARGETS INVOLVED IN THE INFLAMMATION AND TISSUE DAMAGE ASSOCIATED WITH T CELL-DRIVEN AUTOIMMUNE DISEASES, SAID GEOFF MCDONOUGH, M.D., CHIEF EXECUTIVE OFFICER OF GENERATION BIO. OUR AIM IS TO SILENCE THERAPEUTIC T CELL TARGETS WITHOUT IMPACTING OTHER IMMUNE CELL TYPES, UNLOCKING A POWERFUL NEW APPLICATION FOR SIRNA IN THE FIELD. WE PLAN TO SUBMIT OUR FIRST IND IN THE SECOND HALF OF 2026 AND TO ENTER THE CLINIC WITHIN OUR CASH RUNWAY, WHICH IS INTO THE SECOND HALF OF 2027.

GENERATION BIO TO APPLY CTLNP DELIVERY TECHNOLOGY TO DEVELOP SIRNA THERAPEUTICS FOR T CELL-DRIVEN AUTOIMMUNE DISEASES

CAMBRIDGE, MASS., OCT. 22, 2024 (GLOBE NEWSWIRE) -- GENERATION BIO CO. (NASDAQ:GBIO) A BIOTECHNOLOGY COMPANY INNOVATING GENETIC MEDICINES FOR PEOPLE LIVING WITH RARE AND PREVALENT DISEASES, TODAY PRESENTED DATA ON ITS CELL-TARGETED LIPID NANOPARTICLE (CTLNP) AND IMMUNE-QUIET DNA (IQDNA) PLATFORMS AT THE EUROPEAN SOCIETY OF GENE AND CELL THERAPY (ESGCT) 31ST ANNUAL CONGRESS.

Generation Bio Co.

GBIO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Generation Bio Co.

GBIO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

GBIO